Targeted consultation on the guideline for development of new medicinal products for the treatment of rheumatoid arthritis

• Date:
  Tuesday, 7 June 2016, All day
• Location:
  European Medicines Agency, Amsterdam, the Netherlands

In the frame of public consultation on the revision of the guideline on clinical investigation of medicinal products other than non-steroidal anti-inflammatory drugs (NSAIDs) for treatment of rheumatoid arthritis, the European Medicines Agency is hosting a meeting to supplement the ongoing debate.

Documents

Programme - Targeted consultation on development of new medicinal products for the treatment of rheumatoid arthritis

Reference Number: EMA/251741/2016

Invitation for expressions of interest - Targeted consultation on the guideline for development of new medicinal products for the treatment of rheumatoid arthritis (RA)

Reference Number: EMA/251809/2016

Presentation - Introduction: development of the draft guideline rheumatoid arthritis 2015 (revision 2004) (Liesbeth Rook)

Presentation - Session 1: Defining and selecting populations, extrapolation of benefit between populations (Jan Mà¼ller-Berghaus)

Presentation - Session 2: European Medicines Agency consultation meeting on the rheumatoid arthritis guideline (Arantxa Sancho-Là³pez)

Presentation - Session 3: Clinical trial designs in rheumatoid arthritis (Andreas Kouroumalis)